DE122007000028I1 - Sich selbst-zusammenbauende Rekombinante HPV16 Papillomavirus Hüllproteine - Google Patents
Sich selbst-zusammenbauende Rekombinante HPV16 Papillomavirus HüllproteineInfo
- Publication number
- DE122007000028I1 DE122007000028I1 DE200712000028 DE122007000028C DE122007000028I1 DE 122007000028 I1 DE122007000028 I1 DE 122007000028I1 DE 200712000028 DE200712000028 DE 200712000028 DE 122007000028 C DE122007000028 C DE 122007000028C DE 122007000028 I1 DE122007000028 I1 DE 122007000028I1
- Authority
- DE
- Germany
- Prior art keywords
- self
- papillomavirus
- capsid proteins
- envelope proteins
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 241000341655 Human papillomavirus type 16 Species 0.000 title 1
- 108090000565 Capsid Proteins Proteins 0.000 abstract 3
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 3
- 210000000234 capsid Anatomy 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 241000701822 Bovine papillomavirus Species 0.000 abstract 1
- 108091026890 Coding region Proteins 0.000 abstract 1
- 108700005307 Human papillomavirus HPV L1 Proteins 0.000 abstract 1
- 241000701635 Monkey papillomavirus Species 0.000 abstract 1
- 241001631646 Papillomaviridae Species 0.000 abstract 1
- 208000009608 Papillomavirus Infections Diseases 0.000 abstract 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 238000003018 immunoassay Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 238000001338 self-assembly Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/795—Composed of biological material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
- Y10S977/803—Containing biological material in its interior
- Y10S977/804—Containing nucleic acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/918—Immunological
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/927—Diagnostic contrast agent
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94137192A | 1992-09-03 | 1992-09-03 | |
US08/032,869 US5437951A (en) | 1992-09-03 | 1993-03-16 | Self-assembling recombinant papillomavirus capsid proteins |
PCT/US1993/008342 WO1994005792A1 (en) | 1992-09-03 | 1993-09-03 | Self-assembling recombinant papillomavirus capsid proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
DE122007000028I1 true DE122007000028I1 (de) | 2007-07-12 |
Family
ID=25476357
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE200712000029 Pending DE122007000029I1 (de) | 1992-09-03 | 1993-09-03 | Sich selbst-zusammenbauende Rekombinante HPV16 Papillomavirus Hüllproteine |
DE200812000010 Pending DE122008000010I1 (de) | 1992-09-03 | 1993-09-03 | Sich selbst-zusammenbauende rekombinante hpv16 papillomavirus-hüllproteine |
DE200712000027 Pending DE122007000027I1 (de) | 1992-09-03 | 1993-09-03 | Sich selbst-zusammenbauende Rekombinante HPV16 Papillomavirus Hüllproteine |
DE200712000028 Pending DE122007000028I1 (de) | 1992-09-03 | 1993-09-03 | Sich selbst-zusammenbauende Rekombinante HPV16 Papillomavirus Hüllproteine |
DE69333859T Expired - Lifetime DE69333859T2 (de) | 1992-09-03 | 1993-09-03 | Sich selbst-zusammenbauende rekombinante hpv16 papillomavirus hüllproteine |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE200712000029 Pending DE122007000029I1 (de) | 1992-09-03 | 1993-09-03 | Sich selbst-zusammenbauende Rekombinante HPV16 Papillomavirus Hüllproteine |
DE200812000010 Pending DE122008000010I1 (de) | 1992-09-03 | 1993-09-03 | Sich selbst-zusammenbauende rekombinante hpv16 papillomavirus-hüllproteine |
DE200712000027 Pending DE122007000027I1 (de) | 1992-09-03 | 1993-09-03 | Sich selbst-zusammenbauende Rekombinante HPV16 Papillomavirus Hüllproteine |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69333859T Expired - Lifetime DE69333859T2 (de) | 1992-09-03 | 1993-09-03 | Sich selbst-zusammenbauende rekombinante hpv16 papillomavirus hüllproteine |
Country Status (13)
Country | Link |
---|---|
US (10) | US5437951A (de) |
EP (3) | EP1538209A3 (de) |
JP (4) | JP4046758B2 (de) |
AT (1) | ATE302795T1 (de) |
AU (1) | AU2004203609B2 (de) |
CA (1) | CA2143845C (de) |
DE (5) | DE122007000029I1 (de) |
DK (1) | DK0662132T3 (de) |
ES (1) | ES2248791T3 (de) |
FR (2) | FR07C0020I2 (de) |
LU (3) | LU91323I2 (de) |
NL (4) | NL300275I1 (de) |
WO (1) | WO1994005792A1 (de) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5876922A (en) | 1985-07-31 | 1999-03-02 | Institute Pasteur | Papillomavirus probe and a process for in vitro diagnosis of papillomavirus infections |
EP1298211B1 (de) * | 1991-07-19 | 2006-07-12 | The University Of Queensland | Polynukleotidabschnitt des HPV16-Genoms |
US5437951A (en) * | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
US20020164350A1 (en) * | 1992-09-03 | 2002-11-07 | Lowy Douglas R. | Chimeric papillomavirus-like particles |
US5618536A (en) * | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
US8062642B1 (en) * | 1993-03-09 | 2011-11-22 | University Of Rochester | Production of papillomavirus capsid protein and virus-like particles |
US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
DE4415743C2 (de) | 1994-05-04 | 1996-10-10 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
US5888516A (en) * | 1994-05-16 | 1999-03-30 | Merck & Co. Inc. | Recombinant papillomavirus vaccines |
DE69535018T2 (de) * | 1994-05-16 | 2007-02-15 | Merck & Co., Inc. | Papillomavirus vakzine |
AUPM566794A0 (en) * | 1994-05-17 | 1994-06-09 | University Of Queensland, The | Process and product |
AU683564B2 (en) * | 1994-05-17 | 1997-11-13 | University Of Queensland, The | Recombinant papilloma virus L1 |
IL113817A (en) * | 1994-06-30 | 2001-03-19 | Merck & Co Inc | Polynucleotide for vaccination against the umbilical cord virus |
US6613749B1 (en) * | 1994-07-26 | 2003-09-02 | Imperial College Innovations Limited | Papovavirus pseudocapsids and use thereof for exogenous material transfer |
AU717932B2 (en) * | 1994-10-06 | 2000-04-06 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Chimeric papillomavirus-like particles |
AU717647B2 (en) * | 1994-10-06 | 2000-03-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Chimeric papillomavirus-like particles |
WO1996011272A2 (de) * | 1994-10-07 | 1996-04-18 | Medigene Gesellschaft Für Molekularbiologische Diagnostik, Theraphie Und Technologie Mbh | Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung |
AR004464A1 (es) * | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
US5840306A (en) * | 1995-03-22 | 1998-11-24 | Merck & Co., Inc. | DNA encoding human papillomavirus type 18 |
US5820870A (en) * | 1995-03-22 | 1998-10-13 | Merck & Co., Inc. | Recombinant human papillomavirus type 18 vaccine |
IL117459A (en) * | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
US5821087A (en) * | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
DE19526386C1 (de) | 1995-07-19 | 1997-01-02 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
US5874089A (en) * | 1995-10-02 | 1999-02-23 | Georgetown University School Of Medicine | Protecting against canine oral papillomavirus (copy) |
US6908615B1 (en) | 1996-03-18 | 2005-06-21 | Merck & Co., Inc. | DNA encoding human papilloma virus type 18 |
US5725481A (en) | 1996-05-17 | 1998-03-10 | A. Fem Medical Corporation | Method and apparatus for collecting vaginal fluid and exfoliated vaginal cells for diagnostic purposes |
AU732125B2 (en) | 1996-07-17 | 2001-04-12 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Infectious papillomavirus pseudoviral particles |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
WO1998025646A1 (en) * | 1996-12-09 | 1998-06-18 | Merck & Co., Inc. | Synthetic hpv16 virus-like particles |
US6165471A (en) * | 1997-07-03 | 2000-12-26 | University Of Colorado, University Technology Corporation | Homogeneous human papillomavirus capsomere containing compositions, methods for manufacture, and use thereof as diagnostic, prophylactic or therapeutic agents |
US6962777B1 (en) * | 1997-09-05 | 2005-11-08 | Medimmune, Inc. | In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents |
US6228368B1 (en) * | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
CA2229955C (en) | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
US7494658B2 (en) | 1998-02-20 | 2009-02-24 | Medigene Ag | Papilloma virus truncated L1 protein and fusion protein constructs |
US7182947B2 (en) | 1998-02-20 | 2007-02-27 | Medigene Ag | Papillomavirus truncated L1 protein and fusion protein constructs |
US6926897B1 (en) | 1998-03-24 | 2005-08-09 | Medigene Aktiengesellschaft | Medicament for the avoidance or treatment of papillomavirus-specific tumour |
WO2000009157A1 (en) * | 1998-08-14 | 2000-02-24 | Merck & Co., Inc. | Protein delivery system using human papillomavirus virus-like particles |
US6991795B1 (en) | 1998-08-14 | 2006-01-31 | Merck & Co., Inc. | Protein delivery system using human papillomavirus virus-like particles |
US6284532B1 (en) * | 1998-08-17 | 2001-09-04 | Indiana University | Purified human papillomavirus |
US6692752B1 (en) | 1999-09-08 | 2004-02-17 | Smithkline Beecham Biologicals S.A. | Methods of treating human females susceptible to HSV infection |
EP1123114B1 (de) | 1998-10-21 | 2005-12-28 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Virusähnliche partikel zur induktion von autoantikörpern |
AU762114B2 (en) * | 1998-12-11 | 2003-06-19 | University Of Queensland, The | Treatment of papillomavirus infections |
AUPP765398A0 (en) * | 1998-12-11 | 1999-01-14 | University Of Queensland, The | Treatment of papillomavirus infections |
US6689366B1 (en) * | 1998-12-17 | 2004-02-10 | Merck & Co., Inc. | Synthetic virus like particles with heterologous epitopes |
DE69930960T2 (de) * | 1998-12-17 | 2007-04-19 | Merck & Co., Inc. | Synthetische virus-ähnliche partikel mit heterologen epitopen. |
DE19905883C2 (de) * | 1999-02-11 | 2001-05-23 | Deutsches Krebsforsch | Chimäre Virus-ähnliche Partikel bzw. chimäre Capsomere von BPV |
US6551597B1 (en) * | 1999-03-18 | 2003-04-22 | President & Fellows Of Harvard College | Vaccine compositions for human papillomavirus |
DE19925234A1 (de) * | 1999-06-01 | 2000-12-14 | Medigene Ag | Capsomere, stabile Capsomere, Capside, VLPs, oder CVLPs bzw. damit beladenen Zellen und ihre Verwendung in Diagnostik und Therapie |
DE19925199A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
DE19925235A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
US6436402B1 (en) * | 1999-10-15 | 2002-08-20 | Merck & Co., Inc. | Process for making human papillomavirus virus-like particles with improved properties |
US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
US7247433B2 (en) | 2001-08-13 | 2007-07-24 | University Of Rochester | Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles |
US20040063188A1 (en) * | 2002-02-14 | 2004-04-01 | Novavax, Inc. | Kit for treating gastrointestinal tract |
GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
EP1656561A2 (de) * | 2003-03-25 | 2006-05-17 | BUCHNER, Erwin | Verfahren zur frühdiagnose von carcinomen und testkit zu dessen durchführung |
WO2005089164A2 (en) * | 2003-12-31 | 2005-09-29 | Pharmexa Inc. | Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions |
US7879321B2 (en) * | 2004-10-08 | 2011-02-01 | Virxsys Corporation | Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production |
DE602005022759D1 (de) | 2004-12-08 | 2010-09-16 | Gen Probe Inc | Nukleinsäuredetektion aus verschiedenen typen des humanen papillomavirus |
LT5414B (lt) * | 2005-04-13 | 2007-04-25 | Biotechnologijos Institutas | Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
CN1328287C (zh) * | 2005-12-29 | 2007-07-25 | 西安交通大学 | Hpv16 l1蛋白模拟肽及其用于制备hpv16诊断试剂和疫苗的用途 |
GB0612825D0 (en) * | 2006-06-28 | 2006-08-09 | Iti Scotland Ltd | Analyte detection |
GB0616508D0 (en) * | 2006-08-18 | 2006-09-27 | Iti Scotland Ltd | Analyte manipulation and detection |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
LT2484375T (lt) | 2006-09-26 | 2018-07-10 | Infectious Disease Research Institute | Vakcinos kompozicija, turinti sintetinio adjuvanto |
KR101532062B1 (ko) | 2007-03-02 | 2015-06-26 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 신규한 방법 및 조성물 |
CN101677966A (zh) * | 2007-04-18 | 2010-03-24 | 加利福尼亚大学董事会 | 蛋白质改性的纳米滴、组合物和制备方法 |
SG183776A1 (en) * | 2007-08-27 | 2012-09-27 | Univ Colorado | Improved methods for protein production |
AR071910A1 (es) | 2008-05-26 | 2010-07-21 | Cadila Healthcare Ltd | Vacuna combinada para el papiloma humano y el sarampion. vector. huesped. |
GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
EP2414512A1 (de) * | 2009-04-03 | 2012-02-08 | Deutsches Krebsforschungszentrum | Verbesserte herstellung papillomavirus-ähnlicher partikel mit einem modifizierten baculovirus-expressionssystem |
ES2683352T3 (es) | 2009-04-13 | 2018-09-26 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Partículas de HPV y usos de las mismas |
AU2010256461B2 (en) | 2009-06-05 | 2016-03-17 | Access To Advanced Health Institute | Synthetic glucopyranosyl lipid adjuvants |
BRPI0924981B1 (pt) | 2009-06-19 | 2022-02-08 | Eyegene Inc | Composição de vacina para câncer cervical |
WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
WO2011119527A1 (en) * | 2010-03-24 | 2011-09-29 | University Of Rochester | Papillomavirus virus-like particle or capsomere formulation and its use as microbicide |
WO2011127360A1 (en) | 2010-04-08 | 2011-10-13 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | B-cell antigen presenting cell assay |
CA2799205A1 (en) | 2010-05-25 | 2011-12-01 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay and associated strategically-truncated probes |
EP3632463A1 (de) | 2011-04-08 | 2020-04-08 | Immune Design Corp. | Immunogene zusammensetzungen und verfahren zur verwendung der zusammensetzungen zur induzierung humoraler und zellulärer immunreaktionen |
RU2610174C2 (ru) | 2011-06-24 | 2017-02-08 | Мерк Шарп И Доум Корп. | Вакцинные составы против вируса папилломы человека (hpv), содержащие алюминиевый адъювант, и способы их получения |
US20130116408A1 (en) * | 2011-11-05 | 2013-05-09 | Aura Biosciences, Inc. | Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy |
US9700639B2 (en) | 2012-02-07 | 2017-07-11 | Aura Biosciences, Inc. | Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells |
PL2811981T3 (pl) | 2012-02-07 | 2019-09-30 | Infectious Disease Research Institute | Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania |
US20150110824A1 (en) | 2012-03-18 | 2015-04-23 | Glaxosmithkline Biologicals, Sa | Method of vaccination against human papillomavirus |
PT2850431T (pt) | 2012-05-16 | 2018-07-23 | Immune Design Corp | Vacinas para hsv-2 |
KR102039520B1 (ko) | 2013-04-18 | 2019-11-01 | 이뮨 디자인 코포레이션 | 암 치료에 이용하기 위한 gla 단일요법 |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
CA2924684C (en) | 2013-09-18 | 2021-02-09 | Aura Biosciences, Inc. | Virus-like particle conjugates for diagnosis and treatment of tumors |
US11801223B2 (en) | 2013-12-31 | 2023-10-31 | Access To Advanced Health Institute | Single vial vaccine formulations |
US11207339B2 (en) | 2015-10-30 | 2021-12-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Targeted cancer therapy |
US10962534B2 (en) | 2016-02-22 | 2021-03-30 | Boehringer Ingelheim Vetmedica Gmbh | Method for the immobilization of biomolecules |
US11344619B2 (en) | 2016-05-16 | 2022-05-31 | Access To Advanced Health Institute | Formulation containing TLR agonist and methods of use |
JP7195147B2 (ja) | 2016-05-16 | 2022-12-23 | アクセス ツー アドバンスト ヘルス インスティチュート | Peg化リポソームおよび使用方法 |
IL311086A (en) | 2016-06-01 | 2024-04-01 | Access To Advanced Health Inst | Nanoalum particles containing a fixing factor |
EP3638207A1 (de) | 2017-06-15 | 2020-04-22 | Infectious Disease Research Institute | Nanostrukturierte lipidträger sowie stabile emulsionen und ihre verwendung |
US20200276299A1 (en) | 2017-09-08 | 2020-09-03 | Infectious Disease Research Institute | Liposomal formulations comprising saponin and methods of use |
CN114340665A (zh) | 2019-05-25 | 2022-04-12 | 传染病研究所 | 用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法 |
CN110699328B (zh) * | 2019-08-21 | 2022-07-19 | 山东省滨州畜牧兽医研究院 | 一种b型猪肠道病毒及其应用 |
JP2023516904A (ja) | 2020-02-14 | 2023-04-21 | メルク・シャープ・アンド・ドーム・エルエルシー | Hpvワクチン |
US20230310323A1 (en) | 2020-09-04 | 2023-10-05 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
EP4291231A1 (de) | 2021-02-11 | 2023-12-20 | GlaxoSmithKline Biologicals S.A. | Herstellung von hpv-impfstoffen |
WO2023014853A1 (en) | 2021-08-06 | 2023-02-09 | Merck Sharp & Dohme Llc | Hpv vaccine |
WO2023023152A1 (en) | 2021-08-19 | 2023-02-23 | Merck Sharp & Dohme Llc | Thermostable lipid nanoparticle and methods of use thereof |
WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57106626A (en) | 1980-12-22 | 1982-07-02 | Teijin Ltd | Cytotoxic protein complex and its preparation |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
FR2524487B1 (fr) * | 1982-04-05 | 1985-11-22 | Pasteur Institut | Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6089755A (ja) * | 1983-07-01 | 1985-05-20 | フイリツプ・ジヨン・ベア−ド | 診断用試薬及びその製造法並びにそれを用いる診断法 |
EP0133123A1 (de) * | 1983-07-25 | 1985-02-13 | Mgi Pharma, Inc. | Papillomavirus-Immunogene |
US4520113A (en) * | 1984-04-23 | 1985-05-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions |
WO1986005816A1 (en) * | 1985-04-04 | 1986-10-09 | Georgetown University | Type-specific papillomavirus dna sequences and peptides |
US5081029A (en) * | 1985-09-25 | 1992-01-14 | Oncogen | Methods of adoptive immunotherapy for treatment of aids |
US4777239A (en) * | 1986-07-10 | 1988-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic peptides of human papilloma virus |
DE3625257A1 (de) | 1986-07-23 | 1988-02-04 | Behringwerke Ag | Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika |
FR2643817B1 (fr) * | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
US5071757A (en) * | 1986-10-06 | 1991-12-10 | Kreider John W | Methods for propagating fastidious human viruses and for producing purified suspensions thereof |
US5186933A (en) * | 1986-12-30 | 1993-02-16 | Baylor College Of Medicine | Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system |
FR2629458B2 (fr) * | 1987-07-31 | 1991-08-09 | Ire Celltarg Sa | Nouvelles sondes d'acides nucleiques specifiques de differents types de virus de papillome humain |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5180806A (en) * | 1988-05-16 | 1993-01-19 | The Scripps Research Institute | Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods |
US5039607A (en) * | 1988-05-17 | 1991-08-13 | Syntex (U.S.A.) Inc. | Method for immunochromatographic analysis |
US5045447A (en) * | 1989-03-15 | 1991-09-03 | Minson Anthony C | Method of producing antibodies to HPV |
NZ232913A (en) | 1989-03-15 | 1992-08-26 | Gist Brocades Nv | Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations |
NL8902301A (nl) | 1989-09-14 | 1991-04-02 | Rijksuniversiteit | Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins. |
CA2038581A1 (en) | 1990-03-20 | 1991-09-21 | Martin Muller | Seroreactive epitopes of human papillomavirus (hpv) 16 proteins |
SE9001705D0 (sv) * | 1990-05-11 | 1990-05-11 | Medscand Ab | Saett foer diagnostik av virusbaerande tumoerer genom immunoassay |
FR2661921B1 (fr) * | 1990-05-11 | 1992-08-07 | Pasteur Institut | Sonde a papillomavirus (hpv66), notamment pour le diagnostic in vitro d'infections a papillomavirus, pouvant s'accompagner de neoplasies genitales, et produits genetiquement et immunologiquement lies a ce papillomavirus. |
EP1298211B1 (de) * | 1991-07-19 | 2006-07-12 | The University Of Queensland | Polynukleotidabschnitt des HPV16-Genoms |
DE122007000099I1 (de) * | 1992-06-25 | 2008-03-27 | Papillomavirus vakzine | |
US5618536A (en) * | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
US20020164350A1 (en) * | 1992-09-03 | 2002-11-07 | Lowy Douglas R. | Chimeric papillomavirus-like particles |
US5437951A (en) * | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
ES2263406T3 (es) * | 1993-03-09 | 2011-06-06 | The University Of Rochester | Producción de la proteína de capside l1 del papilomavirus humano hpv-11 y partículas de tipo virus. |
US5888516A (en) | 1994-05-16 | 1999-03-30 | Merck & Co. Inc. | Recombinant papillomavirus vaccines |
US5874089A (en) | 1995-10-02 | 1999-02-23 | Georgetown University School Of Medicine | Protecting against canine oral papillomavirus (copy) |
US5758284A (en) * | 1995-11-30 | 1998-05-26 | Lucent Technologies Inc. | Increasing the capacity of a personal communication service system by utilization of the bridged shared line appearance feature |
EP1000157A1 (de) | 1997-07-03 | 2000-05-17 | University Technology Corporation | Zusammensetzungen, die homogene kapsomere des menschlichen papillomavirus enthalten, verfahren zu ihrer herstellung und ihre verwendung in der diagnose, prophylaxe und therapie |
EP1123114B1 (de) | 1998-10-21 | 2005-12-28 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Virusähnliche partikel zur induktion von autoantikörpern |
EP1271151A1 (de) | 2001-06-20 | 2003-01-02 | Virofem Diagnostika GmbH | Testsystem und Verfahren zum Nachweis von HPV Antikörpern |
-
1993
- 1993-03-16 US US08/032,869 patent/US5437951A/en not_active Expired - Lifetime
- 1993-09-03 ES ES93921353T patent/ES2248791T3/es not_active Expired - Lifetime
- 1993-09-03 DK DK93921353T patent/DK0662132T3/da active
- 1993-09-03 DE DE200712000029 patent/DE122007000029I1/de active Pending
- 1993-09-03 DE DE200812000010 patent/DE122008000010I1/de active Pending
- 1993-09-03 JP JP50748194A patent/JP4046758B2/ja not_active Expired - Lifetime
- 1993-09-03 CA CA 2143845 patent/CA2143845C/en not_active Expired - Lifetime
- 1993-09-03 EP EP20040104531 patent/EP1538209A3/de not_active Ceased
- 1993-09-03 DE DE200712000027 patent/DE122007000027I1/de active Pending
- 1993-09-03 WO PCT/US1993/008342 patent/WO1994005792A1/en active IP Right Grant
- 1993-09-03 AT AT93921353T patent/ATE302795T1/de active
- 1993-09-03 DE DE200712000028 patent/DE122007000028I1/de active Pending
- 1993-09-03 EP EP93921353A patent/EP0662132B1/de not_active Expired - Lifetime
- 1993-09-03 EP EP20040078323 patent/EP1621635A3/de not_active Ceased
- 1993-09-03 DE DE69333859T patent/DE69333859T2/de not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/484,503 patent/US5985610A/en not_active Expired - Lifetime
- 1995-06-07 US US08/475,783 patent/US5716620A/en not_active Expired - Lifetime
- 1995-06-07 US US08/472,673 patent/US5709996A/en not_active Expired - Lifetime
- 1995-06-07 US US08/475,782 patent/US5744142A/en not_active Expired - Lifetime
- 1995-06-07 US US08/472,672 patent/US5756284A/en not_active Expired - Lifetime
- 1995-06-07 US US08/472,678 patent/US5871998A/en not_active Expired - Lifetime
-
2001
- 2001-03-30 JP JP2001101791A patent/JP4046949B2/ja not_active Expired - Lifetime
- 2001-04-09 US US09/832,065 patent/US20030050439A1/en not_active Abandoned
-
2003
- 2003-02-21 US US10/371,846 patent/US7220419B2/en not_active Expired - Fee Related
-
2004
- 2004-02-23 JP JP2004046134A patent/JP2004208696A/ja not_active Withdrawn
- 2004-02-24 JP JP2004047227A patent/JP2004194672A/ja not_active Withdrawn
- 2004-08-04 AU AU2004203609A patent/AU2004203609B2/en not_active Expired
-
2006
- 2006-06-09 US US11/450,729 patent/US7361356B2/en not_active Expired - Fee Related
-
2007
- 2007-03-08 LU LU91323C patent/LU91323I2/fr unknown
- 2007-03-08 LU LU91324C patent/LU91324I2/fr unknown
- 2007-03-14 NL NL300275C patent/NL300275I1/nl unknown
- 2007-03-14 NL NL300274C patent/NL300274I1/nl unknown
- 2007-03-14 NL NL300276C patent/NL300276I1/nl unknown
- 2007-03-20 FR FR07C0020C patent/FR07C0020I2/fr active Active
- 2007-12-14 LU LU91388C patent/LU91388I2/en unknown
- 2007-12-14 NL NL300325C patent/NL300325I1/nl unknown
-
2008
- 2008-01-18 FR FR08C0003C patent/FR08C0003I1/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE302795T1 (de) | Sich selbst-zusammenbauende rekombinante hpv16 papillomavirus hüllproteine | |
LU91396I2 (fr) | "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 6,11,16 et 18" -Gardasil/Silgard | |
Lowy et al. | Self-assembling recombinant papillomavirus capsid proteins | |
Schlegel et al. | Protecting against canine oral papillomavirus |